Hormonal contraception in women with endometriosis: a systematic review

References

• Vercellini P, Viganò P, Somigliana E, et al. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol. 2014;10:261–275.
   PubMed Web of Science ®Google Scholar
• Falcone T, Lebovic DI. Clinical management of endometriosis. Obstet Gynecol. 2011;118:691–705.
   PubMed Web of Science ®Google Scholar
• Grandi G, Xholli A, Ferrari S, et al. Intermenstrual pelvic pain, quality of life and mood. Gynecol Obstet Invest. 2013;75:97–100.
   PubMed Web of Science ®Google Scholar
• Duffy JM, Arambage K, Correa FJ, et al. Laparoscopic surgery for endometriosis. Cochrane Database Syst Rev. 2014;4:CD011031.
   Google Scholar
• Shakiba K, Bena JF, McGill KM, et al. Surgical treatment of endometriosis: a 7-year follow-up on the requirement for further surgery. Obstet Gynecol. 2008;111:1285–1292.
   PubMed Web of Science ®Google Scholar
• Leone Roberti Maggiore U, Gupta JK, Ferrero S. Treatment of endometrioma for improving fertility. Eur J Obstet Gynecol Reprod Biol. 2017;209:81–85.
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Bellafronte M, Xholli A, et al. Impact of laparoscopic cystectomy of endometriotic and non-endometriotic cysts on ovarian volume, antral follicle count (AFC) and ovarian Doppler velocimetry. Gynecol Endocrinol. 2016;32:298–301.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Barra F, Leone Roberti Maggiore U. Current and emerging therapeutics for the management of endometriosis. Drugs. 2018;78:995–1012.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Alessandri F, Racca A, et al. Treatment of pain associated with deep endometriosis: alternatives and evidence. Fertil Steril. 2015;104:771–792.
   PubMed Web of Science ®Google Scholar
• Grandi G, Toss A, Cortesi L, et al. The association between endometriomas and ovarian cancer: preventive effect of inhibiting ovulation and menstruation during reproductive life. Biomed Res Int. 2015;2015:1.
   Web of Science ®Google Scholar
• Grandi G, Facchinetti F, Bitzer J. Estradiol in hormonal contraception: real evolution or just same old wine in a new bottle? Eur J Contracept Reprod Health Care. 2017;22:245–246.
   PubMed Web of Science ®Google Scholar
• Grandi G, Cagnacci A, Volpe A. Pharmacokinetic evaluation of desogestrel as a female contraceptive. Expert Opin Drug Metab Toxicol. 2014;10:1–10.
   PubMed Web of Science ®Google Scholar
• Scala C, Leone Roberti Maggiore U, Remorgida V, et al. Drug safety evaluation of desogestrel. Expert Opin Drug Saf. 2013;12:433–444.
   PubMed Web of Science ®Google Scholar
• Dunselman GA, Vermeulen N, Becker C, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29:400–412.
   PubMed Web of Science ®Google Scholar
• Harada T, Momoeda M, Taketani Y, et al. Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial. Fertil Steril. 2008;90:1583–1588.
   PubMed Web of Science ®Google Scholar
• Guzick DS, Huang LS, Broadman BA, et al. Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosis-associated pelvic pain. Fertil Steril. 2011;95:1568–1573.
   PubMed Web of Science ®Google Scholar
• Kitawaki J, Ishihara H, Kiyomizu M, et al. Maintenance therapy involving a tapering dose of danazol or mid/low doses of oral contraceptive after gonadotropin-releasing hormone agonist treatment for endometriosis-associated pelvic pain. Fertil Steril. 2008;89:1831–1835.
   PubMed Web of Science ®Google Scholar
• Takamura M, Koga K, Osuga Y, et al. Post-operative oral contraceptive use reduces the risk of ovarian endometrioma recurrence after laparoscopic excision. Hum Reprod. 2009;24:3042–3048.
   PubMed Web of Science ®Google Scholar
• Scala C, Leone Roberti Maggiore U, Barra F, et al. Norethindrone acetate versus extended-cycle oral contraceptive (Seasonique®) in the treatment of endometriosis symptoms: a prospective open-label comparative study. Eur J Obstet Gynecol Reprod Biol. 2018;222:89–94.
   PubMed Web of Science ®Google Scholar
• Vercellini P, De Giorgi O, Mosconi P, et al. Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis. Fertil Steril. 2002;77:52–61.
   PubMed Web of Science ®Google Scholar
• Razzi S, Luisi S, Ferretti C, et al. Use of a progestogen only preparation containing desogestrel in the treatment of recurrent pelvic pain after conservative surgery for endometriosis. Eur J Obstet Gynecol Reprod Biol. 2007;135:188–190.
   PubMed Web of Science ®Google Scholar
• Morotti M, Remorgida V, Venturini PL, et al. Progestin-only contraception compared with extended combined oral contraceptive in women with migraine without aura: a retrospective pilot study. Eur J Obstet Gynecol Reprod Biol. 2014;183:178–182.
   PubMed Web of Science ®Google Scholar
• Vercellini P, Somigliana E, Daguati R, et al. Postoperative oral contraceptive exposure and risk of endometrioma recurrence. Am J Obstet Gynecol. 2008;198:504.e1.
   PubMed Web of Science ®Google Scholar
• Muzii L, Maneschi F, Marana R, et al. Oral estroprogestins after laparoscopic surgery to excise endometriomas: continuous or cyclic administration? Results of a multicenter randomized study. J Minim Invasive Gynecol. 2011;18:173–178.
   PubMed Web of Science ®Google Scholar
• Cheewadhanaraks S, Choksuchat C, Dhanaworavibul K, et al. Postoperative depot medroxyprogesterone acetate versus continuous oral contraceptive pills in the treatment of endometriosis-associated pain: a randomized comparative trial. Gynecol Obstet Invest. 2012;74:151–156.
   PubMed Web of Science ®Google Scholar
• Seracchioli R, Mabrouk M, Frascà C, et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial. Fertil Steril. 2010;93:52–56.
   PubMed Web of Science ®Google Scholar
• Vercellini P, Pietropaolo G, De Giorgi O, et al. Treatment of symptomatic rectovaginal endometriosis with an estrogen–progestogen combination versus low-dose norethindrone acetate. Fertil Steril. 2005;84:1375–1387.
   PubMed Web of Science ®Google Scholar
• Harada T, Kosaka S, Elliesen J, et al. Ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen for the management of endometriosis-associated pelvic pain: a randomized controlled trial. Fertil Steril. 2017;108:798–805.
   PubMed Web of Science ®Google Scholar
• Mabrouk M, Solfrini S, Frascà C, et al. A new oral contraceptive regimen for endometriosis management: preliminary experience with 24/4-day drospirenone/ethinylestradiol 3 mg/20 mcg. Gynecol Endocrinol. 2012;28:451–454.
   PubMed Web of Science ®Google Scholar
• Caruso S, Iraci M, Cianci S, et al. Comparative, open-label prospective study on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain on 2 mg dienogest/30 μg ethinyl estradiol continuous or 21/7 regimen oral contraceptive. J Endocrinol Invest. 2016;39:923–931.
   PubMed Web of Science ®Google Scholar
• Grandi G, Xholli A, Napolitano A, et al. Pelvic pain and quality of life of women with endometriosis during quadriphasic estradiol valerate/dienogest oral contraceptive: a patient-preference prospective 24-week pilot study. Reprod Sci. 2015;22:626–632.
   PubMed Web of Science ®Google Scholar
• Granese R, Perino A, Calagna G, et al. Gonadotrophin-releasing hormone analogue or dienogest plus estradiol valerate to prevent pain recurrence after laparoscopic surgery for endometriosis: a multi-center randomized trial. Acta Obstet Gynecol Scand. 2015;94:637–645.
   PubMed Web of Science ®Google Scholar
• Morelli M, Sacchinelli A, Venturella R, et al. Postoperative administration of dienogest plus estradiol valerate versus levonorgestrel-releasing intrauterine device for prevention of pain relapse and disease recurrence in endometriosis patients. J Obstet Gynaecol Res. 2013;39:985–990.
   PubMed Web of Science ®Google Scholar
• Vercellini P, Barbara G, Somigliana E, et al. Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis. Fertil Steril. 2010;93:2150–2161.
   PubMed Web of Science ®Google Scholar
• Leone Roberti Maggiore U, Remorgida V, Scala C, et al. Desogestrel-only contraceptive pill versus sequential contraceptive vaginal ring in the treatment of rectovaginal endometriosis infiltrating the rectum: a prospective open-label comparative study. Acta Obstet Gynecol Scand. 2014;93:239–247.
   PubMed Web of Science ®Google Scholar
• Walch K, Unfried G, Huber J, et al. Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis – a pilot study. Contraception. 2009;79:29–34.
   PubMed Web of Science ®Google Scholar
• Vercellini P, Frontino G, De Giorgi O, et al. Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. Fertil Steril. 2003;80:305–309.
   PubMed Web of Science ®Google Scholar
• Tanmahasamut P, Rattanachaiyanont M, Angsuwathana S, et al. Postoperative levonorgestrel-releasing intrauterine system for pelvic endometriosis-related pain: a randomized controlled trial. Obstet Gynecol. 2012;119:519–526.
   PubMed Web of Science ®Google Scholar
• Chen YJ, Hsu TF, Huang BS, et al. Postoperative maintenance levonorgestrel-releasing intrauterine system and endometrioma recurrence: a randomized controlled study. Am J Obstet Gynecol. 2017;216:582.e1–582.e9.
   PubMed Web of Science ®Google Scholar
• Petta CA, Ferriani RA, Abrao MS, et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum Reprod. 2005;20:1993–1998.
   PubMed Web of Science ®Google Scholar
• Bayoglu Tekin Y, Dilbaz B, Altinbas SK, et al. Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing hormone analogue. Fertil Steril. 2011;95:492–496.
   PubMed Web of Science ®Google Scholar
• Taneja A, Kaur S, Soni RK, et al. Evaluating the efficacy of levonorgestrel intrauterine system and danazol for relief of postoperative pain in endometriosis. J Clin Diagn Res. 2017;11:QC10–QC12.
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Tirelli A, Cannoletta M, et al. Effect on insulin sensitivity of Implanon vs. GnRH agonist in women with endometriosis. Contraception. 2005;72:443–446.
   PubMed Web of Science ®Google Scholar
• Yamaguti EM, Brito MB, Ferriani RA, et al. Comparison of the hemostatic effects of a levonorgestrel-releasing intrauterine system and leuprolide acetate in women with endometriosis: a randomized clinical trial. Thromb Res. 2014;134:1193–1197.
   PubMed Web of Science ®Google Scholar
• Engemise SL, Willets JM, Emembolu JO, et al. The effect of the levonorgestrel-releasing intrauterine system, Mirena® on mast cell numbers in women with endometriosis undergoing symptomatic treatment. Eur J Obstet Gynecol Reprod Biol. 2011;159:439–442.
   PubMed Web of Science ®Google Scholar
• Manetta LA, de Paula Martins W, Rosa e Silva JC, et al. Uterine ultrasonographic changes during endometriosis treatment: a comparison between levonorgestrel-releasing intrauterine devices and a gonadotropin-releasing hormone agonist. Ultrasound Med Biol. 2008;34:1914–1918.
   PubMed Web of Science ®Google Scholar
• Ferrari S, Persico P, Di Puppo F, et al. Continuous low-dose oral contraceptive in the treatment of colorectal endometriosis evaluated by rectal endoscopic ultrasonography. Acta Obstet Gynecol Scand. 2012;91:699–703.
   PubMed Web of Science ®Google Scholar
• Ponpuckdee J, Taneepanichskul S. The effects of Implanon in the symptomatic treatment of endometriosis. J Med Assoc Thai. 2005;88:S7–*S10.
   PubMedGoogle Scholar
• Kim MK, Chon SJ, Lee JH, et al. Postoperative levonorgestrel-releasing intrauterine system insertion after gonadotropin-releasing hormone agonist treatment for preventing endometriotic cyst recurrence: a prospective observational study. Reprod Sci. 2018;25:39–43.
   PubMed Web of Science ®Google Scholar
• Lockhat FB, Emembolu JO, Konje JC. The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up. Hum Reprod. 2005;20:789–793.
   PubMed Web of Science ®Google Scholar
• Fedele L, Bianchi S, Zanconato G, et al. Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosis. Fertil Steril. 2001;75:485–488.
   PubMed Web of Science ®Google Scholar
• Taniguchi F, Enatsu A, Ota I, et al. Effects of low dose oral contraceptive pill containing drospirenone/ethinylestradiol in patients with endometrioma. Eur J Obstet Gynecol Reprod Biol. 2015;191:116–120.
   PubMed Web of Science ®Google Scholar
• Lee DY, Bae DS, Yoon BK, et al. Post-operative cyclic oral contraceptive use after gonadotrophin-releasing hormone agonist treatment effectively prevents endometrioma recurrence. Hum Reprod. 2010;25:3050–3054.
   PubMed Web of Science ®Google Scholar
• Yisa SB, Okenwa AA, Husemeyer RP. Treatment of endometriotic catamenial haemoptysis with etonogestrel subdermal implant. BJOG. 2004;111:385–386.
   PubMed Web of Science ®Google Scholar
• Yisa SB, Okenwa AA, Husemeyer RP. Treatment of pelvic endometriosis with etonogestrel subdermal implant (Implanon). J Fam Plann Reprod Health Care. 2005;31:67–70.
   PubMed Web of Science ®Google Scholar
• Al-Jefout M, Palmer J, Fraser IS. Simultaneous use of a levonorgestrel intrauterine system and an etonogestrel subdermal implant for debilitating adolescent endometriosis. Aust N Z J Obstet Gynaecol. 2007;47:247–249.
   PubMed Web of Science ®Google Scholar
• Vercellini P, Somigliana E, Viganò P, et al. Endometriosis: current therapies and new pharmacological developments. Drugs. 2009;69:649–675.
   PubMed Web of Science ®Google Scholar
• Grandi G, Farulla A, Sileo FG, et al. Levonorgestrel-releasing intra-uterine systems as female contraceptives. Expert Opin Pharmacother. 2018;19:677–668.
   PubMed Web of Science ®Google Scholar
• Tafi E, Leone Roberti Maggiore U, Alessandri F, et al. Advances in pharmacotherapy for treating endometriosis. Expert Opin Pharmacother. 2015;16:2465–2483.
   PubMed Web of Science ®Google Scholar
• Ferrero S, Evangelisti G, Barra F. Current and emerging treatment options for endometriosis. Expert Opin Pharmacother. 2018;19:1109–1125.
   PubMed Web of Science ®Google Scholar
• Barra F, Scala C, Ferrero S. Current understanding on pharmacokinetics, clinical efficacy and safety of progestins for treating pain associated to endometriosis. Expert Opin Drug Metab Toxicol. 2018;14:399–415.
   PubMed Web of Science ®Google Scholar
• Quaas AM, Weedin EA, Hansen KR. On-label and off-label drug use in the treatment of endometriosis. Fertil Steril. 2015;103:612–625.
   PubMed Web of Science ®Google Scholar
• Ferrero S. Endometriosis: modern management of an ancient disease. Eur J Obstet Gynecol Reprod Biol. 2017;209:1–2.
   PubMed Web of Science ®Google Scholar
• Winner B, Peipert JF, Zhao Q, et al. Effectiveness of long-acting reversible contraception. N Engl J Med. 2012;366:1998–2007.
   PubMed Web of Science ®Google Scholar
• Klipping C, Duijkers I, Remmers A, et al. Ovulation-inhibiting effects of dienogest in a randomized, dose-controlled pharmacodynamic trial of healthy women. J Clin Pharmacol. 2012;52:1704–1713.
   PubMed Web of Science ®Google Scholar
• Endrikat J, Parke S, Trummer D, et al. Pituitary, ovarian and additional contraceptive effects of an estradiol-based combined oral contraceptive: results of a randomized, open-label study. Contraception. 2013;87:227–234.
   PubMed Web of Science ®Google Scholar
• Vandever MA, Kuehl TJ, Sulak PJ, et al. Evaluation of pituitary-ovarian axis suppression with three oral contraceptive regimens. Contraception. 2008;77:162–170.
   PubMed Web of Science ®Google Scholar
• van den Heuvel MV, van Bragt AJ, Alnabawy AK, et al. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception. 2005;72:168–174.
   PubMed Web of Science ®Google Scholar
• Grandi G, Mueller MD, Papadia A, et al. Inflammation influences steroid hormone receptors targeted by progestins in endometrial stromal cells from women with endometriosis. J Reprod Immunol. 2016;117:30–38.
   PubMed Web of Science ®Google Scholar
• McKinnon B, Mueller M, Montgomery G. Progesterone resistance in endometriosis: an acquired property? Trends Endocrinol Metab. 2018;29:535–548.
   PubMed Web of Science ®Google Scholar
• Upson K, Allison KH, Reed SD, et al. Biomarkers of progestin therapy resistance and endometrial hyperplasia progression. Am J Obstet Gynecol. 2012;207:e1–e8.
   PubMed Web of Science ®Google Scholar
• Vercellini P. Are combined hormonal contraceptives the neglected treatment for symptomatic endometriosis? Fertil Steril. 2018;110:61–62.
   PubMed Web of Science ®Google Scholar